Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 177

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Tumor-reactive antibodies evolve from non-binding and autoreactive precursors

Open access
Mazor, Roei D., Nathan, Nachum, Gilboa, Amit, Stoler-Barak, Liat, Moss, Lihee, Solomonov, Inna, Hanuna, Assaf, Divinsky, Yalin, Shmueli, Merav D., Hezroni, Hadas, Zaretsky, Irina, Mor, Michael, Golani, Ofra, Sabah, Gad, Jakobson-Setton, Ariella, Yanichkin, Natalia, Feinmesser, Meora, Tsoref, Daliah, Salman, Lina, Yeoshoua, Effi, Peretz, Eyal, Erlich, Inna, Cohen, Netta Mendelson, Gershoni, Jonathan M., Freund, Natalia, Merbl, Yifat, Yaari, Gur, Eitan, Ram, Sagi, Irit, Shulman, Ziv·2022·Cell

Abstract

The tumor microenvironment hosts antibody-secreting cells (ASCs) associated with a favorable prognosis in several types of cancer. Patient-derived antibodies have diagnostic and therapeutic potential; yet, it remains unclear how antibodies gain autoreactivity and target tumors. Here, we found that somatic hypermutations (SHMs) promote antibody antitumor reactivity against surface autoantigens in high-grade serous ovarian carcinoma (HGSOC). Patient-derived tumor cells were frequently coated with IgGs. Intratumoral ASCs in HGSOC were both mutated and clonally expanded and produced tumor-reactive antibodies that targeted MMP14, which is abundantly expressed on the tumor cell surface. The reversion of monoclonal antibodies to their germline configuration revealed two types of classes: one dependent on SHMs for tumor binding and a second with germline-encoded autoreactivity. Thus, tumor-reactive autoantibodies are either naturally occurring or evolve through an antigen-driven selection process. These findings highlight the origin and potential applicability of autoantibodies directed at surface antigens for tumor targeting in cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2022.02.012

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 73

  1. Anderson, 2015, Autoantibody signature for the serologic detection of ovarian cancer, J. Proteome Res., 14, 578, 10.1021/pr500908n · DOI
  2. Andreu, 2010, FcRgamma activation regulates inflammation-associated squamous carcinogenesis, Cancer Cell, 17, 121, 10.1016/j.ccr.2009.12.019 · DOI · Paper page
  3. Andrusier, 2007, FireDock: fast interaction refinement in molecular docking, Proteins, 69, 139, 10.1002/prot.21495 · DOI · Paper page
  4. Ashkenazy, 2021, Motifier: an IgOme profiler based on peptide motifs using machine learning, J. Mol. Biol., 433, 167071, 10.1016/j.jmb.2021.167071 · DOI
  5. Auersperg, 2013, Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis?, Gynecol. Oncol., 130, 246, 10.1016/j.ygyno.2013.03.021 · DOI
  6. Balicer, 2017, Digital health nation: Israel’s global big data innovation hub, Lancet, 389, 2451, 10.1016/S0140-6736(17)30876-0 · DOI
  7. Biram, 2019, T cell interactions with B cells during germinal center formation, a three-step model, Immunol. Rev., 288, 37, 10.1111/imr.12737 · DOI
  8. Biswas, 2021, IgA transcytosis and antigen recognition govern ovarian cancer immunity, Nature, 591, 464, 10.1038/s41586-020-03144-0 · DOI · Paper page
  9. Boland, 2019, Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade, Gynecol. Oncol., 152, 251, 10.1016/j.ygyno.2018.11.025 · DOI
  10. Bolotin, 2017, Antigen receptor repertoire profiling from RNA-Seq data, Nat. Biotechnol., 35, 908, 10.1038/nbt.3979 · DOI · Paper page
  11. Bowtell, 2010, The genesis and evolution of high-grade serous ovarian cancer, Nat. Rev. Cancer, 10, 803, 10.1038/nrc2946 · DOI · Paper page
  12. Cathcart, 2016, Interleukin-6 increases matrix metalloproteinase-14 (MMP-14) levels via down-regulation of p53 to drive cancer progression, Oncotarget, 7, 61107, 10.18632/oncotarget.11243 · DOI
  13. Cho, 2015, The extracellular matrix in epithelial ovarian cancer - A piece of a puzzle, Front. Oncol., 5, 245, 10.3389/fonc.2015.00245 · DOI
  14. Cornaby, 2015, B cell epitope spreading: mechanisms and contribution to autoimmune diseases, Immunol. Lett., 163, 56, 10.1016/j.imlet.2014.11.001 · DOI · Paper page
  15. Crowley, 2016, Matrix metalloproteinase-10 is a target of T and B cell responses that correlate with synovial pathology in patients with antibiotic-refractory lyme arthritis, J. Autoimmun., 69, 24, 10.1016/j.jaut.2016.02.005 · DOI
  16. Cui, 2021, Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes robust anti-tumor CD8 T cell responses, Cell, 184, 6101, 10.1016/j.cell.2021.11.007 · DOI · Paper page
  17. Degn, 2017, Clonal evolution of autoreactive germinal centers, Cell, 170, 913, 10.1016/j.cell.2017.07.026 · DOI
  18. DeNardo, 2019, Macrophages as regulators of tumour immunity and immunotherapy, Nat. Rev. Immunol., 19, 369, 10.1038/s41577-019-0127-6 · DOI · Paper page
  19. DeWeerdt, 2021, The origins of ovarian cancer, Nature, 600, S42, 10.1038/d41586-021-03717-7 · DOI
  20. Di Zenzo, 2012, Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface, J. Clin. Invest., 122, 3781, 10.1172/JCI64413 · DOI · Paper page
  21. DiLillo, 2015, Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions, Cancer Immunol. Res., 3, 704, 10.1158/2326-6066.CIR-15-0120 · DOI
  22. Doo, 2019, Checkpoint inhibitors in ovarian cancer: a review of preclinical data, Gynecol. Oncol. Rep., 29, 48, 10.1016/j.gore.2019.06.003 · DOI
  23. Freund, 2009, Phage display selection, analysis, and prediction of B cell epitopes, Curr. Protoc. Immunol., 9, 8
  24. Gnjatic, 2010, Seromic profiling of ovarian and pancreatic cancer, Proc. Natl. Acad. Sci. USA, 107, 5088, 10.1073/pnas.0914213107 · DOI · Paper page
  25. Gupta, 2015, Change-O: A toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data, Bioinformatics, 31, 3356, 10.1093/bioinformatics/btv359 · DOI · Paper page
  26. Hu, 2019, Landscape of B cell immunity and related immune evasion in human cancers, Nat. Genet., 51, 560, 10.1038/s41588-018-0339-x · DOI · Paper page
  27. Jayson, 2014, Ovarian cancer, Lancet, 384, 1376, 10.1016/S0140-6736(13)62146-7 · DOI · Paper page
  28. Kaimal, 2013, Selective blockade of matrix Metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer, Cancer Res., 73, 2457, 10.1158/0008-5472.CAN-12-1426 · DOI
  29. Kamel, 2010, Immunoexpression of matrix metalloproteinase-2 (MMP-2) in malignant ovarian epithelial tumours, J. Obstet. Gynaecol. Can., 32, 580, 10.1016/S1701-2163(16)34527-3 · doi:10.1016/s1701-2163(16)34527-3
  30. Kroeger, 2016, Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer, Clin. Cancer Res., 22, 3005, 10.1158/1078-0432.CCR-15-2762 · DOI · Paper page
  31. Labidi-Galy, 2017, High grade serous ovarian carcinomas originate in the fallopian tube, Nat. Commun., 8, 1093, 10.1038/s41467-017-00962-1 · DOI · Paper page
  32. Ma, 2020, Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer, Cancer Sci., 112, 537, 10.1111/cas.14732 · DOI
  33. Mahmood, 2020, First-line management of advanced high-grade serous ovarian cancer, Curr. Oncol. Rep., 22, 64, 10.1007/s11912-020-00933-8 · DOI
  34. Maletzki, 2012, Ex-vivo clonally expanded B lymphocytes infiltrating colorectal carcinoma are of mature immunophenotype and produce functional IgG, PLoS One, 7, e32639, 10.1371/journal.pone.0032639 · DOI
  35. Mashiach, 2008, FireDock: A web server for fast interaction refinement in molecular docking, Nucleic Acids Res., 36, W229, 10.1093/nar/gkn186 · DOI · Paper page
  36. Mietzner, 2008, Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors, Proc. Natl. Acad. Sci. USA, 105, 9727, 10.1073/pnas.0803644105 · DOI · Paper page
  37. Milne, 2008, Tumor-infiltrating T cells correlate with NY-ESO-1-Specific autoantibodies in ovarian cancer, PLoS One, 3, e3409, 10.1371/journal.pone.0003409 · DOI
  38. Montfort, 2017, A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases, Clin. Cancer Res., 23, 250, 10.1158/1078-0432.CCR-16-0081 · DOI · Paper page
  39. Mose, 2016, Assembly-based inference of B-cell receptor repertoires from short read RNA sequencing data with V’DJer, Bioinformatics, 32, 3729, 10.1093/bioinformatics/btw526 · DOI
  40. Moss, 2009, Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination, Cancer Res., 69, 7121, 10.1158/0008-5472.CAN-08-4151 · DOI
  41. Nelson, 2010, CD20+ B cells: the other tumor-infiltrating lymphocytes, J. Immunol., 185, 4977, 10.4049/jimmunol.1001323 · DOI · Paper page
  42. Nishijima, 2004, Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis, Clin. Exp. Immunol., 138, 357, 10.1111/j.1365-2249.2004.02615.x · DOI
  43. Nzula, 2003, Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas, Cancer Res., 63, 3275
  44. O Donnell, 2014, The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis, PLoS One, 9, e90604, 10.1371/journal.pone.0090604 · DOI
  45. Piccoli, 2015, Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis, Nat. Commun., 6, 7375, 10.1038/ncomms8375 · DOI
  46. Pitzalis, 2014, Ectopic lymphoid-like structures in infection, cancer and autoimmunity, Nat. Rev. Immunol., 14, 447, 10.1038/nri3700 · DOI · Paper page
  47. Prigent, 2016, Scarcity of autoreactive human blood IgA+ memory B cells, Eur. J. Immunol., 46, 2340, 10.1002/eji.201646446 · DOI
  48. Ramalingam, 2016, Morphologic, immunophenotypic, and molecular features of epithelial ovarian cancer, Oncology (Williston Park), 30, 166
  49. Ran, 1976, Tumor-bound immunoglobulins. Evidence for the in vivo coating of tumor cells by potentially cytotoxic anti-tumour antibodies, Int. J. Cancer, 17, 90, 10.1002/ijc.2910170113 · DOI
  50. Rao, 1988, Detection of human ovarian tumor-associated antigens by antibodies isolated from ovarian carcinoma ascitic fluid, Am. J. Obstet. Gynecol., 159, 94, 10.1016/0002-9378(88)90500-5 · doi:10.1016/0002-9378(88)90500-5
  51. Sakata, 2000, Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary, Int. J. Oncol., 17, 673
  52. Sato, 2003, Function blocking autoantibodies Against matrix metalloproteinase-1 in patients with systemic sclerosis, J. Invest. Dermatol., 120, 542, 10.1046/j.1523-1747.2003.12097.x · DOI
  53. Saul, 2016, IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin, Sci. Rep., 6, 29736, 10.1038/srep29736 · DOI
  54. Schroeder, 2013, The role of somatic hypermutation in the generation of pathogenic antibodies in SLE, Autoimmunity, 46, 121, 10.3109/08916934.2012.748751 · DOI
  55. Sharonov, 2020, B cells, plasma cells and antibody repertoires in the tumour microenvironment, Nat. Rev. Immunol., 20, 294, 10.1038/s41577-019-0257-x · DOI · Paper page
  56. Silburn, 1984, Demonstration of tumor-associated immunoglobulin G isolated from immune complexes in ascitic fluid of ovarian cancer, Diagn. Immunol., 2, 30
  57. Tiller, 2008, Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expressionvector cloning, J. Immunol. Methods, 329, 112, 10.1016/j.jim.2007.09.017 · DOI · Paper page
  58. Tiller, 2007, Autoreactivity in human IgG+ memory B cells, Immunity, 26, 205, 10.1016/j.immuni.2007.01.009 · DOI · Paper page
  59. Udi, 2013, Unraveling hidden allosteric regulatory sites in structurally homologues metalloproteases, J. Mol. Biol., 425, 2330, 10.1016/j.jmb.2013.04.009 · DOI
  60. Uppendahl, 2017, Natural killer cell-based immunotherapy in gynecologic malignancy: a review, Front. Immunol., 8, 1825, 10.3389/fimmu.2017.01825 · DOI
  61. Vinuesa, 2009, Dysregulation of germinal centres in autoimmune disease, Nat. Rev. Immunol., 9, 845, 10.1038/nri2637 · DOI · Paper page
  62. Vos, 2021, The role of MMP-14 in ovarian cancer: a systematic review, J. Ovarian Res., 14, 1
  63. Vos, 2016, MMP-14 and CD44 in epithelial-to-mesenchymal transition (EMT) in ovarian cancer, J. Ovarian Res., 9, 53, 10.1186/s13048-016-0262-7 · DOI
  64. Wang, 2021, Diverse functional autoantibodies in patients with COVID-19, medRxiv
  65. Wardemann, 2003, Predominant autoantibody production by early human B cell precursors, Science, 301, 1374, 10.1126/science.1086907 · DOI · Paper page
  66. Webb, 2021, Tissues: the unexplored frontier of antibody mediated immunity, Curr. Opin. Virol., 47, 52, 10.1016/j.coviro.2021.01.001 · DOI
  67. Wieland, 2019, Fc receptors in antimicrobial protection, Curr. Top. Microbiol. Immunol., 423, 119
  68. Wieland, 2021, Defining HPV-specific B cell responses in patients with head and neck cancer, Nature, 597, 274, 10.1038/s41586-020-2931-3 · DOI · Paper page
  69. Witz, 1977, Tumor-bound immunoglobulins: in situ expressions of humoral immunity, Adv. Cancer Res., 25, 95, 10.1016/S0065-230X(08)60633-8 · DOI
  70. Yaari, 2012, Quantifying selection in high-throughput immunoglobulin sequencing data sets, Nucleic Acids Res., 40, e134, 10.1093/nar/gks457 · DOI · Paper page
  71. Yang, 2021, Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues, Science, 372, 738, 10.1126/science.abf6648 · DOI
  72. Ye, 2013, IgBLAST: an immunoglobulin variable domain sequence analysis tool, Nucleic Acids Res., 41, W34, 10.1093/nar/gkt382 · DOI · Paper page
  73. Zaenker, 2016, Autoantibody production in cancer—the humoral immune response toward autologous antigens in cancer patients, Autoimmun. Rev., 15, 477, 10.1016/j.autrev.2016.01.017 · DOI · Paper page

Cited by

See all 177

Metadata

Authors
Mazor, R. D., Nathan, N., Gilboa, A., Stoler-Barak, L., Moss, L., Solomonov, I., Hanuna, A., Divinsky, Y., Shmueli, M. D., Hezroni, H., Zaretsky, I., Mor, M., Golani, O., Sabah, G., Jakobson-Setton, A., Yanichkin, N., Feinmesser, M., Tsoref, D., Salman, L., Yeoshoua, E., Peretz, E., Erlich, I., Cohen, N. M., Gershoni, J. M., Freund, N., Merbl, Y., Yaari, G., Eitan, R., Sagi, I., & Shulman, Z.
Venue
Cell
Publisher
Elsevier BV
Published
2022-03
Volume
185
Issue
7
Pages
1208-1222.e21
ISSN
0092-8674 (ISSN-L)
OpenAlex
W4221041063
Cited by
177
References
8
FWCI
10.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor-reactive antibodies evolve from non-binding and autoreactive precursors. https://app.cochat.ai/papers/10.1016/j.cell.2022.02.012
The paper
Mazor, R. D., Nathan, N., Gilboa, A., Stoler-Barak, L., Moss, L., Solomonov, I., Hanuna, A., Divinsky, Y., Shmueli, M. D., Hezroni, H., Zaretsky, I., Mor, M., Golani, O., Sabah, G., Jakobson-Setton, A., Yanichkin, N., Feinmesser, M., Tsoref, D., Salman, L., . . . Shulman, Z. (2022). Tumor-reactive antibodies evolve from non-binding and autoreactive precursors. Cell. https://doi.org/10.1016/j.cell.2022.02.012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.